FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2785391206> ?p ?o ?g. }

• W2785391206 endingPage "220" @default.
• W2785391206 startingPage "214" @default.
• W2785391206 abstract "Niraparib is an oral poly(ADP ribose) polymerase (PARP) inhibitor that is currently approved by the United States Food and Drug Administration (US FDA) as well as recently approved by the European Medicines Agency (EMA) for the maintenance treatment of women with recurrent ovarian cancer who are in complete or partial response to platinum-based chemotherapy. The mechanisms of action of niraparib include inhibition of PARP enzymatic activity as well as increased formation of PARP-DNA complexes through trapping the PARP enzyme on damaged DNA. Phase I and III studies have demonstrated activity and benefit of niraparib in both BRCA mutated (BRCAm) and BRCA wild-type (BRCAwt) cancers. Phase I testing of niraparib established the maximally tolerated dose of 300mg by mouth (PO) daily, and the phase 3 ENGOT-OV16/NOVA study demonstrated the benefit of niraparib maintenance therapy compared to placebo after completion of and response to platinum-based chemotherapy in both BRCAm and BRCAwt ovarian cancer patient populations. Toxicities seen with niraparib include hematologic, gastrointestinal, fatigue, and cardiovascular. Hematologic toxicities include thrombocytopenia, anemia, neutropenia and leukopenia; upfront dose modification to 200mg niraparib for patients with baseline weight of ≤77kg and/or baseline platelets of ≤150,000K/uL should be considered to avoid significant hematologic toxicity, especially thrombocytopenia, based on recent analyses of the ENGOT-OV16/NOVA study. Cardiovascular toxicities include hypertension, tachycardia, as well as palpitations, and patients should be monitored for hypertension. PARP inhibitors have been associated with low risks of acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS), and the overall risk of AML and MDS is 0.9% of all patients treated with niraparib. Niraparib testing is ongoing in newly diagnosed ovarian cancer patients as maintenance therapy following completion of platinum-based chemotherapy, in BRCAwt cancers as treatment, as well as in combinations with other biologic drugs such as immunotherapy and anti-angiogenic agents." @default.
• W2785391206 created "2018-02-23" @default.
• W2785391206 creator A5058249824 @default.
• W2785391206 creator A5069337573 @default.
• W2785391206 creator A5079485962 @default.
• W2785391206 date "2018-04-01" @default.
• W2785391206 modified "2023-09-29" @default.
• W2785391206 title "The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities" @default.
• W2785391206 cites W1757407923 @default.
• W2785391206 cites W2067560254 @default.
• W2785391206 cites W2126125759 @default.
• W2785391206 cites W2128746885 @default.
• W2785391206 cites W2130078242 @default.
• W2785391206 cites W2138035969 @default.
• W2785391206 cites W2160466424 @default.
• W2785391206 cites W2160784991 @default.
• W2785391206 cites W2171658624 @default.
• W2785391206 cites W2177704039 @default.
• W2785391206 cites W2293618284 @default.
• W2785391206 cites W2334279947 @default.
• W2785391206 cites W2507354250 @default.
• W2785391206 cites W2519148856 @default.
• W2785391206 cites W2528228811 @default.
• W2785391206 cites W2531736191 @default.
• W2785391206 cites W2547556928 @default.
• W2785391206 cites W2551563085 @default.
• W2785391206 cites W2605456582 @default.
• W2785391206 cites W2737389832 @default.
• W2785391206 cites W2754327139 @default.
• W2785391206 doi "https://doi.org/10.1016/j.ygyno.2018.01.011" @default.
• W2785391206 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29397193" @default.
• W2785391206 hasPublicationYear "2018" @default.
• W2785391206 type Work @default.
• W2785391206 sameAs 2785391206 @default.
• W2785391206 citedByCount "51" @default.
• W2785391206 countsByYear W27853912062018 @default.
• W2785391206 countsByYear W27853912062019 @default.
• W2785391206 countsByYear W27853912062020 @default.
• W2785391206 countsByYear W27853912062021 @default.
• W2785391206 countsByYear W27853912062022 @default.
• W2785391206 countsByYear W27853912062023 @default.
• W2785391206 crossrefType "journal-article" @default.
• W2785391206 hasAuthorship W2785391206A5058249824 @default.
• W2785391206 hasAuthorship W2785391206A5069337573 @default.
• W2785391206 hasAuthorship W2785391206A5079485962 @default.
• W2785391206 hasConcept C121608353 @default.
• W2785391206 hasConcept C126322002 @default.
• W2785391206 hasConcept C143998085 @default.
• W2785391206 hasConcept C2776694085 @default.
• W2785391206 hasConcept C2777063308 @default.
• W2785391206 hasConcept C2780427987 @default.
• W2785391206 hasConcept C2780873365 @default.
• W2785391206 hasConcept C71924100 @default.
• W2785391206 hasConcept C98274493 @default.
• W2785391206 hasConceptScore W2785391206C121608353 @default.
• W2785391206 hasConceptScore W2785391206C126322002 @default.
• W2785391206 hasConceptScore W2785391206C143998085 @default.
• W2785391206 hasConceptScore W2785391206C2776694085 @default.
• W2785391206 hasConceptScore W2785391206C2777063308 @default.
• W2785391206 hasConceptScore W2785391206C2780427987 @default.
• W2785391206 hasConceptScore W2785391206C2780873365 @default.
• W2785391206 hasConceptScore W2785391206C71924100 @default.
• W2785391206 hasConceptScore W2785391206C98274493 @default.
• W2785391206 hasIssue "1" @default.
• W2785391206 hasLocation W27853912061 @default.
• W2785391206 hasLocation W27853912062 @default.
• W2785391206 hasOpenAccess W2785391206 @default.
• W2785391206 hasPrimaryLocation W27853912061 @default.
• W2785391206 hasRelatedWork W1999706042 @default.
• W2785391206 hasRelatedWork W2020274747 @default.
• W2785391206 hasRelatedWork W2058955695 @default.
• W2785391206 hasRelatedWork W2354070956 @default.
• W2785391206 hasRelatedWork W2364106504 @default.
• W2785391206 hasRelatedWork W2375501759 @default.
• W2785391206 hasRelatedWork W2378088005 @default.
• W2785391206 hasRelatedWork W2382857639 @default.
• W2785391206 hasRelatedWork W2401101517 @default.
• W2785391206 hasRelatedWork W2409812054 @default.
• W2785391206 hasVolume "149" @default.
• W2785391206 isParatext "false" @default.
• W2785391206 isRetracted "false" @default.
• W2785391206 magId "2785391206" @default.
• W2785391206 workType "article" @default.